TransEnterix, Inc. (NYSEAMERICAN:TRXC) shares gapped down before the market opened on Wednesday . The stock had previously closed at $2.18, but opened at $2.23. TransEnterix shares last traded at $2.21, with a volume of 1254181 shares changing hands.

Separately, Zacks Investment Research lowered TransEnterix from a “buy” rating to a “hold” rating in a report on Friday, January 11th.

TransEnterix (NYSEAMERICAN:TRXC) last posted its earnings results on Tuesday, February 26th. The medical instruments supplier reported ($0.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.01). The company had revenue of $7.50 million during the quarter, compared to analyst estimates of $7.35 million. TransEnterix’s revenue was up 120.6% compared to the same quarter last year.

In related news, CFO Joseph P. Slattery sold 88,871 shares of the stock in a transaction dated Friday, February 22nd. The stock was sold at an average price of $3.25, for a total transaction of $288,830.75. Following the completion of the sale, the chief financial officer now directly owns 44,929 shares in the company, valued at approximately $146,019.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp grew its stake in shares of TransEnterix by 123.6% in the 2nd quarter. Northern Trust Corp now owns 597,765 shares of the medical instruments supplier’s stock worth $2,606,000 after buying an additional 330,384 shares during the last quarter. First Trust Advisors LP purchased a new stake in TransEnterix during the 3rd quarter valued at $654,000. Russell Investments Group Ltd. purchased a new stake in TransEnterix during the 3rd quarter valued at $325,000. US Bancorp DE boosted its stake in TransEnterix by 170.6% during the 3rd quarter. US Bancorp DE now owns 27,060 shares of the medical instruments supplier’s stock valued at $157,000 after purchasing an additional 17,060 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in TransEnterix by 40.1% during the 3rd quarter. Wells Fargo & Company MN now owns 168,146 shares of the medical instruments supplier’s stock valued at $975,000 after purchasing an additional 48,102 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/transenterix-trxc-shares-gap-down-to-2-23/2905014.html.

TransEnterix Company Profile (NYSEAMERICAN:TRXC)

TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.

Further Reading: How Important is Technical Analysis of Stocks

Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.